Pharmacy Recommendations Not Addressed or Documented
Summary
The facility did not ensure that a licensed pharmacist’s monthly drug regimen review recommendations were acted upon and documented by the physician for residents reviewed with pharmacy recommendations. Surveyors found no documented physician response and no indication that pharmacist recommendations were followed up on for 5 of 5 residents reviewed: R3, R6, R33, R58, and R66. For R58, who had diagnoses including major depressive disorder, epilepsy, extrapyramidal and movement disorder, schizophrenia, pica, and unspecified dementia with behavioral disturbance, the record showed psychotropic medication use and a BIMS score of 12. Pharmacy reviews documented recommendations related to lorazepam and gradual dose reduction for haloperidol, olanzapine, and trazodone, but the reviews in the chart were not dated and there was no documented physician response or evidence the recommendations were acted upon. The DON stated the facility had obtained copies from the pharmacist and that no other copies were available at the facility. For R33, who had diagnoses including major depressive disorder, psychosis, and dementia, the MDS documented use of antipsychotic, antidepressant, and anticonvulsant medications. Pharmacy recommendations in June, August, and September 2025 were not addressed by the facility, and the DON had no additional information about why they were not addressed. For R6, with diagnoses including dysphagia, chronic respiratory failure, COPD, dementia, and major depressive disorder, pharmacy recommendations from July and August 2025 advised discontinuing or changing several medications, including cetirizine, guaifenesin ER, lidocaine ointment, Mylanta, and simethicone, but there was no evidence of physician follow-up. For R3, with diagnoses including bipolar disorder and anxiety disorder, pharmacy recommendations from June, July, and August 2025 included discontinuing or changing artificial tears, ibuprofen, ondansetron, and oxycodone, and obtaining TSH monitoring due to levothyroxine use; there was no evidence these recommendations were followed up on, and the DON stated the previous DON had been responsible for bringing pharmacy recommendations to the provider’s attention. For R66, who had diagnoses including depression, transient ischemic attack, and cerebral infarction, the admission MDS showed a BIMS score of 15 and intact cognition. The EMR did not contain monthly medication reviews from admission through September 2025, and the only pharmacy recommendation provided was incomplete, with no response, signature, or date. The DON stated there was no documentation showing the recommendation was addressed or how it was addressed, and the NHA was informed that there was no evidence the pharmacy recommendation had been addressed by the health provider.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.